Laboratory Corporation of America Holdings (NYSE:LH) – Equities research analysts at William Blair lowered their FY2017 EPS estimates for Laboratory Corporation of America Holdings in a research report issued to clients and investors on Tuesday. William Blair analyst A. Murphy now expects that the medical research company will earn $9.53 per share for the year, down from their previous estimate of $9.56. William Blair also issued estimates for Laboratory Corporation of America Holdings’ Q4 2017 earnings at $2.38 EPS, Q1 2018 earnings at $2.39 EPS, Q2 2018 earnings at $2.66 EPS, Q4 2018 earnings at $2.56 EPS and FY2018 earnings at $10.39 EPS.

A number of other equities analysts have also recently commented on LH. KeyCorp reaffirmed a “hold” rating on shares of Laboratory Corporation of America Holdings in a research note on Tuesday, September 26th. ValuEngine cut Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Robert W. Baird reaffirmed a “hold” rating and issued a $166.00 price target on shares of Laboratory Corporation of America Holdings in a research note on Tuesday, October 17th. Barclays PLC lifted their price target on Laboratory Corporation of America Holdings from $182.00 to $183.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. Finally, Zacks Investment Research cut Laboratory Corporation of America Holdings from a “buy” rating to a “hold” rating in a research note on Tuesday, September 26th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $169.00.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/brokers-issue-forecasts-for-laboratory-corporation-of-america-holdings-fy2017-earnings-lh/1721335.html.

Laboratory Corporation of America Holdings (NYSE:LH) opened at $151.91 on Thursday. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.89 and a quick ratio of 1.75. The company has a market capitalization of $15,559.11, a P/E ratio of 16.43, a price-to-earnings-growth ratio of 1.62 and a beta of 0.87. Laboratory Corporation of America Holdings has a 12 month low of $123.36 and a 12 month high of $164.22.

Laboratory Corporation of America Holdings (NYSE:LH) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.38 by $0.08. The company had revenue of $2.60 billion for the quarter, compared to analysts’ expectations of $2.55 billion. Laboratory Corporation of America Holdings had a return on equity of 16.75% and a net margin of 7.40%. Laboratory Corporation of America Holdings’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period last year, the firm posted $2.25 EPS.

In other Laboratory Corporation of America Holdings news, Director Dwight Gary Gilliland sold 971 shares of the business’s stock in a transaction on Monday, October 30th. The stock was sold at an average price of $153.52, for a total value of $149,067.92. Following the sale, the director now directly owns 3,501 shares of the company’s stock, valued at $537,473.52. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider F Samuel Eberts III sold 31,500 shares of the business’s stock in a transaction on Friday, August 25th. The stock was sold at an average price of $155.22, for a total value of $4,889,430.00. Following the completion of the sale, the insider now directly owns 31,894 shares in the company, valued at $4,950,586.68. The disclosure for this sale can be found here. Insiders have sold 209,871 shares of company stock worth $32,892,005 over the last 90 days. 0.90% of the stock is currently owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in LH. Aperio Group LLC boosted its holdings in Laboratory Corporation of America Holdings by 23.3% in the second quarter. Aperio Group LLC now owns 51,991 shares of the medical research company’s stock worth $8,014,000 after acquiring an additional 9,813 shares in the last quarter. APG Asset Management N.V. lifted its holdings in shares of Laboratory Corporation of America Holdings by 10.6% during the second quarter. APG Asset Management N.V. now owns 423,427 shares of the medical research company’s stock valued at $65,267,000 after purchasing an additional 40,642 shares in the last quarter. Quantitative Systematic Strategies LLC lifted its holdings in shares of Laboratory Corporation of America Holdings by 28.7% during the second quarter. Quantitative Systematic Strategies LLC now owns 6,949 shares of the medical research company’s stock valued at $1,058,000 after purchasing an additional 1,550 shares in the last quarter. Regentatlantic Capital LLC lifted its holdings in shares of Laboratory Corporation of America Holdings by 0.5% during the second quarter. Regentatlantic Capital LLC now owns 1,696 shares of the medical research company’s stock valued at $261,000 after purchasing an additional 8 shares in the last quarter. Finally, Shell Asset Management Co. lifted its holdings in shares of Laboratory Corporation of America Holdings by 4.1% during the second quarter. Shell Asset Management Co. now owns 12,689 shares of the medical research company’s stock valued at $1,956,000 after purchasing an additional 500 shares in the last quarter. 92.96% of the stock is currently owned by institutional investors and hedge funds.

About Laboratory Corporation of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Earnings History and Estimates for Laboratory Corporation of America Holdings (NYSE:LH)

Receive News & Ratings for Laboratory Corporation of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corporation of America Holdings and related companies with Analyst Ratings Network's FREE daily email newsletter.